Iain Stuart - 17 Mar 2022 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role
Chief Scientific Officer
Signature
/s/ Mutya Harsch, attorney-in-fact for Iain Stuart
Issuer symbol
VYNE
Transactions as of
17 Mar 2022
Net transactions value
$0
Form type
4
Filing time
18 Mar 2022, 17:10:08 UTC
Previous filing
04 Jan 2022
Next filing
04 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNE Common Stock Award $0 +75,000 +49% $0.000000 228,879 17 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYNE Stock Options Award $0 +75,000 $0.000000 75,000 17 Mar 2022 Common Stock 75,000 $0.6100 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.
F2 The awards vest over four years, 25% on March 31, 2023 and 6.25% every three months thereafter, ending on March 31, 2026.